Lexaria Bioscience: Proprietary Drug Delivery Technology

Improving the way active pharmaceutical ingredients enter the bloodstream

Lexaria Bioscience has developed a proprietary drug delivery technology, DehydraTECH™. It improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods as well as increasing the effectiveness of fat-soluble active molecules and drugs.

Furthermore, Lexaria is commercializing it in both North America and around the world. “It’s a process that we have come up with and it helps to deliver drugs more quickly and more effectively from the mouth to the bloodstream and even across the blood brain barrier,” says CEO and Chairman, Chris Bunka.

DehydraTECH™ is currently being investigated for hypertension, antiviral drug delivery, HIV AIDS and COVID-19. It’s also being investigated for oral nicotine instead of having to smoke.

In 2021, Lexaria plans to conduct a great amount of applied R&D. With that data collection, they hope to knock on the doors of the Big Pharma and the biotech industries.

“I think our valuation could go up not 10 times, but 100 times and still be justifiable based on the size of the markets that we are chasing,” says Bunka.

For more information on Lexaria Bioscience Corp. (CSE: LXX, NASDAQ: LEXX) please click on the request investor info button.